Early Onset and Familial Gastric Cancer Registry
- Conditions
- Gastric Cancer
- Interventions
- Behavioral: questionnaires
- Registration Number
- NCT00582257
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is to establish a gastric cancer registry. A registry is a database of information. With the registry, we can learn more about the genetic causes of gastric cancer in order to develop better methods of early diagnosis, prevention, and treatment of gastric cancers. As part of this study, you will be asked to join a registry of families who are affected with various forms of gastric cancer. These registries are important because they may help physicians better manage gastric cancer now and in the future. Participating in the Early Onset and Familial Gastric Cancer Registry can also be educational for families, since it will provide important information to patients, families, and physicians. All of this will help to further our understanding of genetic causes of gastric cancer and eventually, help determine better ways to diagnose, treat, and survey patients with gastric cancer and people who may have a higher risk for gastric cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 971
Patient/Relative Cohort:
Must meet one or more criteria below:
-
A person with a diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma confirmed at the treating institution.
-
A person without gastric or GEJ adenocarcinoma who has or had a first degree relative eligible for a High Risk Genetic sub-group (EOGC/FGC).
- Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.
- Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.
-
A person without gastric or GEJ adenocarcinoma who has a personal family history of a genetic mutation associated with the development of gastric or GEJ adenocarcinoma (i.e. family history of CDH1 mutation).
II. Must be willing to provide a blood sample for germline DNA. These individuals will sign the "Patient/Relative Consent". Following enrollment, we will assign individuals to the appropriate High Genetic Risk or Low Genetic Risk groups based on the age of diagnosis and their family history.
Subject Exclusion Criteria
Patients are ineligible for the study if they:
- Have any condition, which in the opinion of the primary MSK clinician or investigators precludes their ability to provide informed consent.
- Relatives of patients that are not eligible for the High Genetic Risk Cohorts who are less than 18 years of age are excluded.
- Relatives of patients eligible for the High Genetic Risk Cohorts who do not have a proband available to join the study are excluded. (Unless there is a known CDH1 mutation in the family).
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description High Genetic Risk: questionnaires Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease. Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives. Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer. Low Genetic Risk: Closed to Accrual questionnaires Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort. Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone.
- Primary Outcome Measures
Name Time Method Create registry of families w/ early onset & familial gastric cancer for analysis of risk factors, family history and unidentified susceptibility genes. Create cohorts of pts w/ low genetic risk for the development of gastric cancer December 2010
- Secondary Outcome Measures
Name Time Method To determine the incidence of CDH1 germline mutations among individuals with early onset or familial gastric cancer and their relatives. December 2010 To determine the gastric pathology evident from a single baseline endoscopic screen of unaffected first-degree relatives of a patient with EOGC or FGC. December 2010
Trial Locations
- Locations (10)
University of Southern California - Norris Cancer Hospital
🇺🇸Los Angeles, California, United States
Memorial Sloan Kettering Cancer Center at Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth
🇺🇸Middletown, New Jersey, United States
Memorial Sloan Kettering Cancer Center at Commack
🇺🇸Commack, New York, United States
Queens Cancer Center of Queens Hospital
🇺🇸Jamaica, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Weill Cornell Medical Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
🇺🇸Rockville Centre, New York, United States
Memorial Sloan Kettering Westchester
🇺🇸West Harrison, New York, United States
Obafemi Awolowo University Teaching Hospital
🇳🇬Ile-Ife, Nigeria